Sino Biopharmaceutical Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sino Biopharmaceutical Limited
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
Private Company Edition: VC deals are surging this year for cell and gene therapy firms, according to ARM’s third quarter report. Also, Vivo Capital and the CF Foundation plan to invest nearly $2bn in health care and life science opportunities, and Akeso completes $150m series D.
Following a positive Phase III data readout for KX2-391, Athenex requests dissolution of its recent deal conferring rights to the drug in China to Chongqing Jingdong Junzhuo. TaiwanJ licenses Asian rights outside its home market for JK-122 to Newsoara.
Chi-Med's China-focused strategy is paying off with positive Phase III top-line results for its home-grown VEGF inhibitor fruquintinib, keeping it on track to for a filing this year. But competition looms.
- Drug Delivery
- Generic Drugs
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Beijing Tide Pharmaceutical Co Ltd, Jiangsu Chia Tai Tianqing Pharmaceutical Co Ltd, Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd, Jiangsu Chia Tai Fenghai Pharmaceutical Co Ltd, Qingdao Chia Tai Haier Pharmaceutical Co Ltd, Jiangsu Chia Tai Qing Jiang Pharmaceutical Co Ltd, etc.